Converting peptides into drug leads by lipidation

Current Medicinal Chemistry

Volumn 19, Issue 11, 2012, Pages 1602-1618

  Zhang, L ^a   Bulaj, G ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

ADME; Lipidated peptide; Lipidation; Lipoamino acids; Peptide; Peptide sar; Peptide secondary structure; Peptide self assembling; Peptide serum stability; Peptide synthesis

Indexed keywords

ANGIOTENSIN; CALCITONIN DERIVATIVE; CONOTOXIN; DESMOPRESSIN; DICARBOXYLIC ACID; DIPALMITOYLPHOSPHATIDYLCHOLINE; ENKEPHALIN; GALANIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; HEXANOIC ACID; LIPOSOME; LIRAGLUTIDE; MASTOPARAN; OCTREOTIDE; OLIGOMER; PANCREAS POLYPEPTIDE; PEPTIDE; PROTIRELIN; TETRAXETAN; UNSATURATED FATTY ACID; VAPREOTIDE;

ACYLATION; ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHEMICAL PROCEDURES; CYTOTOXICITY; DRUG DESIGN; HUMAN; HYDROPHILICITY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIPIDATION; LIPOPHILICITY; MEMBRANE BINDING; MYRISTYLATION; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RECEPTOR BINDING;

DRUG DESIGN; LIPIDS; LIPOYLATION; PEPTIDES;

EID: 84860532030     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799945003     Document Type: Article

References (180)

1. Strieker, M.; Marahiel, M. A. The structural diversity of acidic lipopeptide antibiotics. ChemBioChem, 2009, 10 4, 607-616.
2. Hosoda, H.; Kojima, M.; Mizushima, T.; Shimizu, S.; Kangawa, K. Structural divergence of human Ghrelin. J. Biol. Chem., 2003, 278 1, 64-70.
3. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402 6762, 656-660.
4. Linder, M. E.; Deschenes, R. J. Palmitoylation: policing protein stability and traffic. Nat. Rev. Mol. Cell Biol., 2007, 8 1, 74-84.
5. Walsh, C. T.; Garneau-Tsodikova, S.; Gatto, G. J. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed., 2005, 44 45, 7342-7372.
6. Brunsveld, L.; Kuhlmann, J.; Waldmann, H. Synthesis of palmitoylated Raspeptides and -proteins. Methods, 2006, 40 2, 151-165.
7. Irwin, N.; Green, B. D.; Gault, V. A.; Greer, B.; Harriott, P.; Bailey, C. J.; Flatt, P. R.; O'Harte, F. P. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J. Med. Chem., 2005, 48 4, 1244-1250.
8. Laczkó, I.; Váró, G.; Bottka, S.; Bálint, Z.; Illyés, E.; Vass, E.; Bertrand, J.-R.; Malvy, C.; Hollósi, M. N-terminal acylation of the SV40 nuclear localization signal peptide enhances its oligonucleotide binding and membrane translocation efficiencies. Arch. Biochem. Biophys., 2006, 454 2, 146-154.
9. Tarwadi; Jazayeri, J. A.; Prankerd, R. J.; Pouton, C. W. Preparation and in vitro evaluation of novel lipopeptide transfection agents for efficient gene delivery. Bioconjugate Chem., 2008, 19 4, 940-950.
10. Robinson, L. R.; Fitzgerald, N. C.; Doughty, D. G.; Dawes, N. C.; Berge, C. A.; Bissett, D. L. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int. J. Cosmet Sci., 2005, 27 3, 155-160.
11. Kellam, B.; Drouillat, B.; Dekany, G.; Starr, M. S.; Toth, I. Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int. J. Pharm., 1998, 161 1, 55-64.
12. Uchiyama, T.; Kotani, A.; Tatsumi, H.; Kishida, T.; Okamoto, A.; Okada, N.; Murakami, M.; Fujita, T.; Fujiwara, Y.; Kiso, Y.; Muranishi, S.; Yamamoto, A. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats. Pharm. Res., 2000, 17 12, 1461-1467.
13. Wang, J.; Hogenkamp, D. J.; Tran, M.; Li, W. Y.; Yoshimura, R. F.; Johnstone, T. B.; Shen, W. C.; Gee, K. W. Reversible lipidization for the oral delivery of leu-enkephalin. J. Drug Target., 2006, 14 3, 127-136.
14. Bulaj, G.; Green, B. R.; Lee, H. K.; Robertson, C. R.; White, K.; Zhang, L.; Sochanska, M.; Flynn, S. P.; Scholl, E. A.; Pruess, T. H.; Smith, M. D.; White, H. S. Design, synthesis, and characterization of high-affinity, systemicallyactive galanin analogues with potent anticonvulsant activities. J. Med. Chem., 2008, 51 24, 8038-8047.
15. Green, B. R.; White, K. L.; McDougle, D. R.; Zhang, L.; Klein, B.; Scholl, E. A.; Pruess, T. H.; White, H. S.; Bulaj, G. Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities. J. Pept. Sci., 2010, 16 9, 486-495.
16. Robertson, C. R.; Scholl, E. A.; Pruess, T. H.; Green, B. R.; White, H. S.; Bulaj, G. Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. J. Med. Chem., 2010, 53 4, 1871-1875.
17. White, H. S.; Scholl, E. A.; Klein, B. D.; Flynn, S. P.; Pruess, T. H.; Green, B. R.; Zhang, L.; Bulaj, G. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models. Neurotherapeutics, 2009, 6 2, 372-380.
18. Zhang, L.; Robertson, C. R.; Green, B. R.; Pruess, T. H.; White, H. S.; Bulaj, G. Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J. Med. Chem., 2009, 52 5, 1310-1316.
19. Irwin, N.; O'Harte, F. P. M.; Gault, V. A.; Green, B. D.; Greer, B.; Harriott, P.; Bailey, C. J.; Flatt, P. R. GIP (Lys16PAL) and GIP (Lys37PAL): novel longacting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem., 2006, 49 3, 1047-1054.
20. Madsen, K.; Knudsen, L. B.; Agersoe, H.; Nielsen, P. F.; Thøgersen, H.; Wilken, M.; Johansen, N. L. Structure-activity and protraction relationship of long-acting Glucagon-like Peptide-1 derivatives:importance of fatty acid length, polarity, and bulkiness. J. Med. Chem., 2007, 50 24, 6126-6132.
21. Bellmann-Sickert, K.; Elling, C. E.; Madsen, A. N.; Little, P. B.; Lundgren, K.; Gerlach, L.-O.; Bergmann, R.; Holst, B.; Schwartz, T. W.; Beck-Sickinger, A. G. Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J. Med. Chem., 2011, 54 8, 2658-2667.
22. Johannessen, L.; Remsberg, J.; Gaponenko, V.; Adams, K. M.; Barchi, J. J.; Tarasov, S. G.; Jiang, S.; Tarasova, N. I. Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors. ChemBioChem, 2011, 12 6, 914-921.
23. Asada, H.; Douen, T.; Mizokoshi, Y.; Fujita, T.; Murakami, M.; Yamamoto, A.; Muranishi, S. Stability of acyl derivatives of Insulin in the small intestine: relative importance of Insulin association characteristics in aqueous solution. Pharm. Res., 1994, 11 8, 1115-1120.
24. Asada, H.; Douen, T.; Waki, M.; Adachi, S.; Fujita, T.; Yamamoto, A.; Muranishi, S. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J. Pharm. Sci., 1995, 84 6, 682-687.
25. Hashimoto, M.; Takada, K.; Kiso, Y.; Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res., 1989, 6 2, 171-176.
26. Hashizume, M.; Douen, T.; Murakami, M.; Yamamoto, A.; Takada, K.; Muranishi, S. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J. Pharm. Pharmacol., 1992, 44 7, 555-559.
27. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Larsen, U. D.; Ribel, U.; Markussen, J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J., 1995, 312 3, 725-731.
28. Muranishi, S.; Murakami, M.; Hashidzume, M.; Yamada, K.; Tajima, S.; Kiso, Y. Trials of lipid modification of peptide hormones for intestinal delivery. J. Controlled Release, 1992, 19(1-3), 179-188.
29. Myers, S. R.; Yakubu-Madus, F. E.; Johnson, W. T.; Baker, J. E.; Cusick, T. S.; Williams, V. K.; Tinsley, F. C.; Kriauciunas, A.; Manetta, J.; Chen, V. J. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes, 1997, 46 4, 637-642.
30. + that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells. Int. J. Pharm., 1994, 105 3, 241-247.
31. Green, B. R.; Smith, M.; White, K. L.; White, H. S.; Bulaj, G. Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering. ACS Chem. Neurosci., 2011, 2 1, 55-56.
32. Dasgupta, P.; Mukherjee, R. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. Br. J. Pharmacol., 2000, 129 1, 101-109.
33. Dasgupta, P.; Singh, A. T.; Mukherjee, R. Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability. Pharm. Res., 1999, 16 7, 1047-1053.
34. Timofeeva, O. A.; Gaponenko, V.; Lockett, S. J.; Tarasov, S. G.; Jiang, S.; Michejda, C. J.; Perantoni, A. O.; Tarasova, N. I. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol., 2007, 2 12, 799-809.
35. Fujita, T.; Kawahara, I.; Quan, Y.-s.; Hattori, K.; Takenaka, K.; Muranishi, S.; Yamamoto, A. Permeability characteristics of Tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors. Pharm. Res., 1998, 15 9, 1387-1392.
36. Setoh, K.; Murakami, M.; Araki, N.; Fujita, T.; Yamamoto, A.; Muranishi, S. Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J. Pharm. Pharmacol., 1995, 47 10, 808-811.
37. Yodoya, E.; Uemura, K.; Tenma, T.; Fujita, T.; Murakami, M.; Yamamoto, A.; Muranishi, S. Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J. Pharmacol. Exp. Ther., 1994, 271 3, 1509-1513.
38. Muranishi, S.; Sakai, A.; Yamada, K.; Murakami, M.; Takada, K.; Kiso, Y. Lipophilic peptides: synthesis of Lauroyl Thyrotropin-Releasing Hormone and its biological activity. Pharm. Res., 1991, 8 5, 649-652.
39. Tanaka, K.; Fujita, T.; Yamamoto, Y.; Murakami, M.; Yamamoto, A.; Muranishi, S. Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim. Biophys. Acta - Biomembranes, 1996, 1283 1, 119-126.
40. Maletínskâ, L.; Neugebauer, W.; Parê, M.-C.; Jacqueline, P.; Pham, D.; Escher, E. Lipid masking and reactivation of Angiotensin analogues. Helv. Chim. Acta, 1996, 79 7, 2023-2034.
41. Maletínskâ, L.; Neugebauer, W.; Jacqueline, P.; Lefebvre, M.; Escher, E. Angiotensin analogues palmitoylated in positions 1 and 4. J. Med. Chem., 1997, 40 20, 3271-3279.
42. Ekrami, H. M.; Kennedy, A. R.; Shen, W.-C. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett., 1995, 371 3, 283-286.
43. Honeycutt, L.; Wang, J.; Ekrami, H.; Shen, W. C. Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate. Pharm. Res., 1996, 13 9, 1373-1377.
44. Wang, J.; Shen, W. C. Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice. Int. J. Pharm., 2000, 204(1-2), 111-116.
45. Wang, J.; Shen, D.; Shen, W.-C. Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated antidiuretic activity. Pharm. Res., 1999, 16 11, 1674-1679.
46. Bednarek, M. A.; Feighner, S. D.; Pong, S. S.; McKee, K. K.; Hreniuk, D. L.; Silva, M. V.; Warren, V. A.; Howard, A. D.; Van der Ploeg, L. H.; Heck, J. V. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem., 2000, 43 23, 4370-4376.
47. Chollet, C.; Meyer, K.; Beck-Sickinger, A. G. Ghrelin-a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. J. Pept. Sci., 2009, 15 11, 711-730.
48. Matsumoto, M.; Hosoda, H.; Kitajima, Y.; Morozumi, N.; Minamitake, Y.; Tanaka, S.; Matsuo, H.; Kojima, M.; Hayashi, Y.; Kangawa, K. Structureactivity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem. Biophys. Res. Commun., 2001, 287 1, 142-146.
49. Cheng, W.; Lim, L. Y. Comparison of reversible and nonreversible aqueoussoluble lipidized conjugates of Salmon Calcitonin. Mol. Pharmaceutics, 2008, 5 4, 610-621
50. Cheng, W.; Satyanarayanajois, S.; Lim, L. Y. Aqueous-soluble, nonreversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm. Res., 2007, 24 1, 99-110.
51. Wang, J.; Chow, D.; Heiati, H.; Shen, W. C. Reversible lipidization for the oral delivery of salmon calcitonin. J. Controlled Release, 2003, 88 3, 369-380.
52. Lundin, S.; Møss, J.; Bundgaard, H.; Artursson, P. Absorption of thyrotropin-releasing hormone (TRH) and a TRH prodrug in a human intestinal cell line (Caco-2). Int. J. Pharm., 1991, 76 3, R1-R4.
53. Yuan, L.; Wang, J.; Shen, W. C. Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm. Res., 2005, 22 2, 220-227.
54. Green, B. R.; Catlin, P.; Zhang, M. M.; Fiedler, B.; Bayudan, W.; Morrison, A.; Norton, R. S.; Smith, B. J.; Yoshikami, D.; Olivera, B. M.; Bulaj, G. Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity. Chem. Biol., 2007, 14 4, 399-407.
55. Lee, H. K.; Smith, M. D.; Smith, B. J.; Grussendorf, J.; Xu, L.; Gillies, R. J.; White, H. S.; Bulaj, G. Anticonvulsant Met-enkephalin analogues containing backbone spacers reveal alternative non-opioid signaling in the brain. ACS Chem. Biol., 2009, 4 8, 659-671.
56. Itoh, F.; Nishikimi, Y.; Hasuoka, A.; Yoshioka, Y.; Yukishige, K.; Tanida, S.; Aono, T. Synthesis and structure-activity relationships of TAN-1511 analogues as potent hematopoietic agents. Chem. Pharm. Bull. (Tokyo), 1998, 46 2, 255-273.
57. Oh, H. S.; Kim, S.; Cho, H.; Lee, K. H. Development of novel lipid-peptide hybrid compounds with antibacterial activity from natural cationic antibacterial peptides. Bioorg. Med. Chem. Lett., 2004, 14 5, 1109-1113.
58. Zarandi, M.; Varga, J. L.; Schally, A. V.; Horvath, J. E.; Toller, G. L.; Kovacs, M.; Letsch, M.; Groot, K.; Armatis, P.; Halmos, G. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 12, 4610-4615.
59. Amon, M. A.; Ali, M.; Bender, V.; Chan, Y.-N.; Toth, I.; Manolios, N. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim. Biophys. Acta, 2006, 1763 8, 879-888.
60. Chan, E.; Amon, M.; Marano, R. J.; Wimmer, N.; Kearns, P. S.; Manolios, N.; Rakoczy, P. E.; Toth, I. Novel cationic lipophilic peptides for oligodeoxynucleotide delivery. Bioorg. Med. Chem., 2007, 15 12, 4091-4097.
61. Pignatello, R.; Pecora, T. M. Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity. Pharmazie, 2007, 62 9, 663-667.
62. Dulhunty, A. F.; Cengia, L.; Young, J.; Pace, S. M.; Harvey, P. J.; Lamb, G. D.; Chan, Y. N.; Wimmer, N.; Toth, I.; Casarotto, M. G. Functional implications of modifying RyR-activating peptides for membrane permeability. Br. J. Pharmacol., 2005, 144 6, 743-754.
63. Hayes, P. Y.; Ross, B. P.; Thomas, B. G.; Toth, I. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg. Med. Chem., 2006, 14 1, 143-152.
64. Ross, B. P.; Toth, I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv., 2005, 2 3, 277-287.
65. Lee, K. C.; Carlson, P. A.; Goldstein, A. S.; Yager, P.; Gelb, M. H. Protection of a decapeptide from proteolytic cleavage by lipidation and self-assembly into high-axial-ratio microstructures: a kinetic and structural study. Langmuir, 1999, 15 17, 5500-5508.
66. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y.-J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A., 2009, 106 14, 5801-5806.
67. Lee, S.; Kim, K.; Kumar, T. S.; Lee, J.; Kim, S. K.; Lee, D. Y.; Lee, Y.-k.; Byun, Y. Synthesis and biological properties of Insulin-deoxycholic acid chemical conjugates. Bioconjugate Chem., 2005, 16 3, 615-620.
68. Lee, S.; Lee, J.; Lee, D.; Kim, S.; Lee, Y.; Byun, Y. A new drug carrier, Nadeoxycholyl-L-lysyl-methylester, for enhancing insulin absorption in the intestine. Diabetologia, 2005, 48 3, 405-411.
69. Blanchfield, J. T.; Dutton, J. L.; Hogg, R. C.; Gallagher, O. P.; Craik, D. J.; Jones, A.; Adams, D. J.; Lewis, R. J.; Alewood, P. F.; Toth, I. Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. J. Med. Chem., 2003, 46 7, 1266-1272.
70. Pignatello, R.; Noce, C.; Campisi, A.; Acquaviva, R.; Bucolo, C.; Puglisi, G.; Toth, I. Evaluation of cell tolerability of a series of lipoamino acids using biological membranes and a biomembrane model. Curr. Drug Deliv., 2007, 4 2, 109-121.
71. Ross, B. P.; Braddy, A. C.; McGeary, R. P.; Blanchfield, J. T.; Prokai, L.; Toth, I. Micellar aggregation and membrane partitioning of bile salts, fatty acids, sodium dodecyl sulfate, and sugar-conjugated fatty acids: correlation with hemolytic potency and implications for drug delivery. Mol. Pharm., 2004, 1 3, 233-245.
72. Ross, B. P.; De Cruz, S. E.; Lynch, T. B.; Davis-Goff, K.; Toth, I. Design, synthesis, and evaluation of a liposaccharide drug delivery agent: application to the gastrointestinal absorption of gentamicin. J. Med. Chem., 2004, 47 5, 1251-1258.
73. Toth, I. A novel chemical approach to drug delivery: lipidic amino acid conjugates. J. Drug Target., 1994, 2 3, 217-239.
74. Görmer, K.; Waldmann, H.; Brunsveld, L. In: Comprehensive Natural Products II, Mander, L., Lui, H.-W., Ed.; Elsevier: Oxford, 2010; pp. 531-585.
75. Magee, T.; Seabra, M. C. Fatty acylation and prenylation of proteins: what's hot in fat. Curr. Opin. Cell Biol., 2005, 17 2, 190-196.
76. Resh, M. D. Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Cell. Signal., 1996, 8 6, 403-412.
77. Ben Mohamed, L.; Wechsler, S. L.; Nesburn, A. B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis., 2002, 2 7, 425-431.
78. Raulin, J. Development in lipid drugs. Mini. Rev. Med. Chem., 2005, 5 5, 489-498.
79. Zhong, W.; Skwarczynski, M.; Toth, I. Lipid Core Peptide System for gene, drug, and vaccine delivery. Aust. J. Chem., 2009, 62 9, 956-967.
80. Wong, A.; Toth, I. Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem., 2001, 8 9, 1123-1136.
81. Yagi, N.; Yano, Y.; Hatanaka, K.; Yokoyama, Y.; Okuno, H. Synthesis and evaluation of a novel lipid-peptide conjugate for functionalized liposome. Bioorg. Med. Chem. Lett., 2007, 17 9, 2590-2593.
82. Jerala, R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin. Invest. Drugs, 2007, 16 8, 1159-1169.
83. Toniolo, C.; Crisma, M.; Formaggio, F.; Peggion, C.; Epand, R. F.; Epand, R. M. Lipopeptaibols, a novel family of membrane active, antimicrobial peptides. Cell. Mol. Life Sci., 2001, 58 9, 1179-1188.
84. Cavalli, S.; Kros, A. Scope and applications of amphiphilic alkyl-and lipopeptides. Adv. Mater., 2008, 20 3, 627-631.
85. Charron, G.; Wilson, J.; Hang, H. C. Chemical tools for understanding protein lipidation in eukaryotes. Curr. Opin. Chem. Biol., 2009, 13 4, 382-391.
86. Peters, C.; Wagner, M.; Volkert, M.; Waldmann, H. Bridging the gap between cell biology and organic chemistry: chemical synthesis and biological application of lipidated peptides and proteins. Naturwissenschaften, 2002, 89 9, 381-390.
87. Silvius, J. R. Lipidated peptides as tools for understanding the membrane interactions of lipid-modified proteins. Curr. Top. Membr., 2002, 52, 371-395.
88. Epand, R. M. Biophysical studies of lipopeptide-membrane interactions. Biopolymers, 1997, 43 1, 15-24.
89. Yamamoto, A.; Morishita, Y.; Sugishita, S.; Hayami, T.; Okada, N.; Fujita, T.; Muranishi, S. Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across the intestinal membranes by chemical modification with various fatty acids. Drug Metab. Pharmacokinet., 2003, 18 1, 23-32.
90. Yamamoto, A.; Setoh, K.; Murakami, M.; Shironoshita, M.; Kobayashi, T.; Fujimoto, K.; Okada, N.; Fujita, T.; Muranishi, S. Enhanced transdermal delivery of phenylalanyl-glycine by chemical modification with various fatty acids. Int. J. Pharm., 2003, 250 1, 119-128.
91. Macquaire, F.; Baleux, F.; Giaccobi, E.; Huynh-Dinh, T.; Neumann, J. M.; Sanson, A. Peptide secondary structure induced by a micellar phospholipidic interface: proton NMR conformational study of a lipopeptide. Biochemistry, 1992, 31 9, 2576-2582.
92. Pakalns, T.; Haverstick, K. L.; Fields, G. B.; McCarthy, J. B.; Mooradian, D. L.; Tirrell, M. Cellular recognition of synthetic peptide amphiphiles in self-assembled monolayer films. Biomaterials, 1999, 20(23-24), 2265-2279.
93. Qahwash, I. M.; Boire, A.; Lanning, J.; Krausz, T.; Pytel, P.; Meredith, S. C. Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. J. Biol. Chem., 2007, 282 51, 36987-36997.
94. Giragossian, C.; Nardi, E.; Savery, C.; Pellegrini, M.; Meini, S.; Maggi, C. A.; Papini, A. M.; Mierke, D. F. Structural characterization of lipopeptide agonists for the bradykinin B2 receptor. Biopolymers, 2001, 58 5, 511-520.
95. Forns, P.; Lauer-Fields, J. L.; Gao, S.; Fields, G. B. Induction of protein-like molecular architecture by monoalkyl hydrocarbon chains. Biopolymers, 2000, 54 7, 531-546.
96. Malkar, N. B.; Lauer-Fields, J. L.; Juska, D.; Fields, G. B. Characterization of peptide-amphiphiles possessing cellular activation sequences. Biomacromolecules, 2003, 4 3, 518-528.
97. Takahashi, Y.; Ueno, A.; Mihara, H. Optimization of hydrophobic domains in peptides that undergo transformation from alpha-helix to beta-fibril. Bioorg. Med. Chem., 1999, 7 1, 177-185.
98. Etzerodt, T.; Henriksen, J. R.; Rasmussen, P.; Clausen, M. H.; Andresen, T. L. Selective acylation enhances membrane charge sensitivity of the antimicrobial peptide Mastoparan-X. Biophys. J., 2011, 100 2, 399-409.
99. Japelj, B.; Zorko, M.; Majerle, A.; Pristovsek, P.; Sanchez-Gomez, S.; Martinez de Tejada, G.; Moriyon, I.; Blondelle, S. E.; Brandenburg, K.; Andra, J.; Lohner, K.; Jerala, R. The acyl group as the central element of the structural organization of antimicrobial lipopeptide. J. Am. Chem. Soc., 2007, 129 5, 1022-1023.
100. Yu, Y.-C.; Berndt, P.; Tirrell, M.; Fields, G. B. Self-assembling amphiphiles for construction of protein molecular architecture. J. Am. Chem. Soc., 1996, 118 50, 12515-12520.
101. Cui, H.; Webber, M. J.; Stupp, S. I. Self-assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials. Peptide Sci., 2010, 94 1, 1-18.
102. Gazit, E. Self-assembled peptide nanostructures: the design of molecular building blocks and their technological utilization. Chem. Soc. Rev., 2007, 36, 1263-1269.
103. Kokkoli, E.; Mardilovich, A.; Wedekind, A.; Rexeisen, E. L.; Garg, A.; Craig, J. A. Self-assembly and applications of biomimetic and bioactive peptide-amphiphiles. Soft Matter., 2006, 2 12, 1015-1024.
104. Scanlon, S.; Aggeli, A. Self-assembling peptide nanotubes. Nano Today, 2008, 3(3-4), 22-30.
105. Hartgerink, J. D.; Beniash, E.; Stupp, S. I. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc. Natl. Acad. Sci. U. S. A., 2002, 99 8, 5133-5138.
106. Weronski, K. J.; Diez-Pérez, I.; Busquets, M. A.; López-Iglesias, C.; Girona, V.; Prat, J. Interaction of lipidated GBV-C/HGV NS3 (513-522) and (505-514) peptides with phospholipids monolayer. An AFM study. Colloids Surf., B Biointerfaces, 2010, 75 1, 25-33.
107. Reig, F.; Haro, I.; Polo, D.; Egea, M. A.; Alsina, M. A. Interfacial interactions of hydrophobic peptides with lipid bilayers. J. Colloid Interface Sci., 2002, 246 1, 60-69.
108. Brunsveld, L.; Waldmann, H.; Huster, D. Membrane binding of lipidated Ras peptides and proteins - the structural point of view. Biochim. Biophys. Acta - Biomembranes, 2009, 1788 1, 273-288.
109. Eisenberg, S.; Henis, Y. I. Interactions of Ras proteins with the plasma membrane and their roles in signaling. Cell. Signal., 2008, 20 1, 31-39.
110. Almiñana, N.; Alsina, M. A.; Reig, F. New GHK hydrophobic derivatives: Interaction with phospholipid bilayers. Colloids Surf., B Biointerfaces, 2007, 57 2, 243-249.
111. Peitzsch, R. M.; McLaughlin, S. Binding of acylated peptides and fatty acids to phospholipid vesicles: Pertinence to myristoylated proteins. Biochemistry, 1993, 32 39, 10436-10443.
112. Gatto, E.; Mazzuca, C.; Stella, L.; Venanzi, M.; Toniolo, C.; Pispisa, B. Effect of peptide lipidation on membrane perturbing activity: a comparative study on two trichogin analogues. J. Phys. Chem. B, 2006, 110 45, 22813-22818.
113. Koda, Y.; Del Borgo, M.; Wessling, S. T.; Lazarus, L. H.; Okada, Y.; Toth, I.; Blanchfield, J. T. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg. Med. Chem., 2008, 16 11, 6286-6296.
114. Tenma, T.; Yodoya, E.; Tashima, S.; Fujita, T.; Murakami, M.; Yamamoto, A.; Muranishi, S. Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm. Res., 1993, 10 10, 1488-1492.
115. Yamamoto, A. Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids. Nippon Rinsho, 1998, 56 3, 601-607.
116. Nelson, A. R.; Borland, L.; Allbritton, N. L.; Sims, C. E. Myristoyl-based transport of peptides into living cells. Biochemistry, 2007, 46 51, 14771-14781.
117. Heinemann, L.; Sinha, K.; Weyer, C.; Loftager, M.; Hirschberger, S.; Heise, T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med., 1999, 16 4, 332-338.
118. Choi, J.-K.; Ho, J.; Curry, S.; Qin, D.; Bittman, R.; Hamilton, J. A. Interactions of very long-chain saturated fatty acids with serum albumin. J. Lipid Res., 2002, 43 7, 1000-1010.
119. Chuang, V. T. G.; Otagiri, M. Stereoselective binding of human serum albumin. Chirality, 2006, 18 3, 159-166.
120. Hamilton, J. A. Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. Prog. Lipid Res., 2004, 43 3, 177-199.
121. Spector, A. A. Fatty acid binding to plasma albumin. J. Lipid Res., 1975, 16 3, 165-179.
122. Bhattacharya, A. A.; Grüne, T.; Curry, S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol., 2000, 303 5, 721-732.
123. Fujiwara, S.; Amisaki, T. Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Biophys. J., 2008, 94 1, 95-103.
124. Petitpas, I.; Grüne, T.; Bhattacharya, A. A.; Curry, S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol., 2001, 314 5, 955-960.
125. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Markussen, J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci., 1997, 86 12, 1365-1368.
126. Bellmann-Sickert, K.; Beck-Sickinger, A. G. Palmitoylated SDF1α shows increased resistance against proteolytic degradation in liver homogenates. ChemMedChem, 2011, 6 1, 193-200.
127. Rivett, D. E.; Hewish, D.; Kirkpatrick, A.; Werkmeister, J. Inhibition of membrane-active peptides by fatty acid-peptide hybrids. J. Protein Chem., 1999, 18 3, 291-295.
128. Yang, P.; Abe, S.; Sato, Y.; Yamashita, T.; Matsuda, F.; Hamayasu, T.; Imai, K.; Suzuki, K. A palmitoyl conjugate of insect pentapeptide Yamamarin arrests cell proliferation and respiration. J. Insect Biotech. Seric., 2007, 76, 263-269.
129. Gault, V. A.; Hunter, K.; Irwin, N.; Greer, B.; Green, B. D.; Harriott, P.; O'Harte, F. P.; Flatt, P. R. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3) GIP receptor antagonist in type 2 diabetes. Biol. Chem., 2007, 388 2, 173-179.
130. O'Harte, F. P.; Hunter, K.; Gault, V. A.; Irwin, N.; Green, B. D.; Greer, B.; Harriott, P.; Bailey, C. J.; Flatt, P. R. Antagonistic effects of two novel GIP analogs, (Hyp3) GIP and (Hyp3) GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. Am. J. Physiol-Endo. M., 2007, 292 6, E1674-1682.
131. Gutniak, M. K.; Linde, B.; Holst, J. J.; Efendic, S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care, 1994, 17 9, 1039-1044.
132. Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136 8, 3585-3596.
133. Vilsboll, T.; Agerso, H.; Krarup, T.; Holst, J. J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol Metab., 2003, 88 1, 220-224.
134. Agersø, H.; Jensen, L. B.; Elbrønd, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 2002, 45 2, 195-202.
135. Knudsen, L. B.; Nielsen, P. F.; Huusfeldt, P. O.; Johansen, N. L.; Madsen, K.; Pedersen, F. Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 2000, 43 9, 1664-1669.
136. Ribel, U.; Larsen, M. O.; Rolin, B.; Carr, R. D.; Wilken, M.; Sturis, J.; Westergaard, L.; Deacon, C. F.; Knudsen, L. B. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucoseintolerant pigs. Eur. J. Pharmcol., 2002, 451 2, 217-225.
137. Chicharro, C.; Granata, C.; Lozano, R.; Andreu, D.; Rivas, L. N-terminal fatty acid substitution increases the leishmanicidal activity of CA (1-7) M (2-9), a cecropin-melittin hybrid peptide. Antimicrob. Agents Chemother., 2001, 45 9, 2441-2449.
138. Fujita, T.; Fujita, T.; Morikawa, K.; Tanaka, H.; Iemura, O.; Yamamoto, A.; Muranishi, S. Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids: Synergistic effects of acylation and absorption enhancers. Int. J. Pharm., 1996, 134(1-2), 47-57.
139. Robertson, C. R.; Flynn, S. P.; White, H. S.; Bulaj, G. Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat. Prod. Rep., 2011, 28 4, 741-762.
140. Ogawa, T.; Araki, M.; Miyamae, T.; Okayama, T.; Hagiwara, M.; Sakurada, S.; Morikawa, T. Synthesis and antinociceptive activity of orally active opioid peptides: improvement of oral bioavailability by esterification. Chem. Pharm. Bull. (Tokyo), 2003, 51 7, 759-771.
141. Heavner, G. A.; Kroon, D. J.; Audhya, T.; Goldstein, G. Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides, 1986, 7 6, 1015-1019.
142. Bergeon, J. A.; Toth, I. Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of L-Glu-L-Trp-NH2. Bioorg. Med. Chem., 2007, 15 22, 7048-7057.
143. Blanchfield, J. T.; Lew, R. A.; Smith, A. I.; Toth, I. The stability of lipidic analogues of GnRH in plasma and kidney preparations: the stereoselective release of the parent peptide. Bioorg. Med. Chem. Lett., 2005, 15 6, 1609-1612.
144. Rist, B.; Wieland, H. A.; Willim, K. D.; Beck-Sickinger, A. G. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor. J. Pept. Sci., 1995, 1 5, 341-348.
145. Heise, T.; Tack, C. J.; Cuddihy, R.; Davidson, J.; Gouet, D.; Liebl, A.; Romero, E.; Mersebach, H.; Dykiel, P.; Jorde, R. A new-generation ultralongacting basal Insulin with a bolus boost compared with Insulin Glargine in Insulin-naive people with type 2 diabetes. Diabetes Care, 2011, 34 3, 669-674.
146. Bundgaard, H.; Moss, J. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res., 1990, 7 9, 885-892.
147. Møss, J.; Buur, A.; Bundgaard, H. Prodrugs of peptides. 8. In vitro study of intestinal metabolism and penetration of thyrotropin-releasing hormone (TRH) and its prodrugs. Int. J. Pharm., 1990, 66(1-3), 183-191.
148. Cini, E.; Lampariello, L. R.; Rodriquez, M.; Taddei, M. Synthesis and application in SPPS of a stable amino acid isostere of palmitoyl cysteine. Tetrahedron, 2009, 65 4, 844-848.
149. Shechter, Y.; Heldman, E.; Sasson, K.; Bachar, T.; Popov, M.; Fridkin, M. Delivery of neuropeptides from the periphery to the brain: studies with Enkephalin. ACS Chem. Neurosci., 2010, 1 5, 399-406.
150. Blanchfield, J.; Toth, I. Lipid, sugar and liposaccharide based delivery systems 2. Curr. Med. Chem., 2004, 11 17, 2375-2382.
151. Namane, A.; Gouyette, C.; Fillion, M. P.; Fillion, G.; Huynh Dinh, T. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem., 1992, 35 16, 3039-3044.
152. Simerska, P.; Abdel-Aal, A.-B. M.; Fujita, Y.; Moyle, P. M.; McGeary, R. P.; Batzloff, M. R.; Olive, C.; Good, M. F.; Toth, I. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J. Med. Chem., 2008, 51 5, 1447-1452.
153. Toth, I.; Malkinson, J. P.; Flinn, N. S.; Drouillat, B.; Horvath, A.; Erchegyi, J.; Idei, M.; Venetianer, A.; Artursson, P.; Lazorova, L.; Szende, B.; Keri, G. Novel lipoamino acid-and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. J. Med. Chem., 1999, 42 19, 4010-4013.
154. Wu, S.; Campbell, C.; Koda, Y.; Blanchfield, J. T.; Toth, I. Investigation of the route of absorption of lipid and sugar modified leu-enkephalin analogues and their enzymatic stability using the caco-2 cell monolayer system. Med. Chem., 2006, 2 2, 203-211.
155. Kaiya, H.; Kodama, S.; Ishiguro, K.; Matsuda, K.; Uchiyama, M.; Miyazato, M.; Kangawa, K. Ghrelin-like peptide with fatty acid modification and Oglycosylation in the red stingray, Dasyatis akajei. BMC Biochem., 2009, 10, 30.
156. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305 5689, 1466-1470.
157. Wolfson, W. Aileron staples peptides. Chemistry & biology, 2009, 16 9, 910-912.
158. Takahashi, Y.; Ueno, A.; Mihara, H. Design of a peptide undergoing α-β structural transition and Amyloid fibrillogenesis by the introduction of a hydrophobic defect. Chem. Eur. J., 1998, 4 12, 2475-2484.
159. Blanchfield, J. T.; Toth, I. Modification of peptides and other drugs using lipoamino acids and sugars. Methods Mol. Biol., 2005, 298, 45-61.
160. Lee, H. K.; Zhang, L.; Smith, M. D.; White, H. S.; Bulaj, G. Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. ChemMedChem, 2009, 4 3, 400-405.
161. Zhang, L.; Lee, H. K.; Pruess, T. H.; White, H. S.; Bulaj, G. Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin. J. Med. Chem., 2009, 52 6, 1514-1517.
162. Rijkers, D. T. S.; Kruijtzer, J. A. W.; Killian, J. A.; Liskamp, R. M. J. A convenient solid phase synthesis of S-palmitoyl transmembrane peptides. Tetrahedron Lett., 2005, 46 19, 3341-3345.
163. Isidro-Llobet, A.; AÌvarez, M.; Albericio, F. Amino acid-protecting groups. Chem. Rev., 2009, 109 6, 2455-2504.
164. Bycroft, B. W.; Chan, W. C.; Chhabra, S. R.; Hone, N. D. A novel lysineprotecting procedure for continuous flow solid phase synthesis of branched peptides. J. Chem. Soc., Chem. Commun., 1993(9), 778-779.
165. Diaz-Mochon, J. J.; Bialy, L.; Bradley, M. Full orthogonality between Dde and Fmoc: the direct synthesis of PNA-Peptide Conjugates. Org. Lett., 2004, 6 7, 1127-1129.
166. Kan, T.; Fukuyama, T. Ns strategies: a highly versatile synthetic method for amines. Chem. Commun., 2004(4), 353-359.
167. Narayan, R. S.; Van Nieuwenhze, M. S. Versatile and stereoselective syntheses of orthogonally protected beta-methylcysteine and beta- methyllanthionine. Org. Lett., 2005, 7 13, 2655-2658.
168. Kadereit, D.; Deck, P.; Heinemann, I.; Waldmann, H. Acid-labile protecting groups for the synthesis of lipidated peptides. Chemistry, 2001, 7 6, 1184-1193.
169. Palomo, J. M.; Lumbierres, M.; Waldmann, H. Efficient solid-phase lipopeptide synthesis employing the ellman sulfonamide linker. Angew. Chem. Int. Ed., 2006, 45 3, 477-481.
170. Carpino, L. A.; Krause, E.; Sferdean, C. D.; Schümann, M.; Fabian, H.; Bienert, M.; Beyermann, M. Synthesis of 'difficult' peptide sequences: application of a depsipeptide technique to the Jung-Redemann 10-and 26-mers and the amyloid peptide A[beta] (1-42). Tetrahedron Lett., 2004, 45 40, 7519-7523.
171. Cruz, L. J.; Cuevas, C.; Canedo, L. M.; Giralt, E.; Albericio, F. Total solidphase synthesis of marine cyclodepsipeptide IB-01212. J. Org. Chem., 2006, 71 9, 3339-3344.
172. Ludolph, B.; Eisele, F.; Waldmann, H. Solid-phase synthesis of lipidated peptides. J Am Chem Soc, 2002, 124 21, 5954-5955.
173. Ponsati I Obiols, B.; Canas I Poblet, M.; Jodas I Farres, G.; Clemente Rodriguez, J.; Barcadit I Cabado, J. EP 1179537. July 30, 2008.
174. Zhang, A. J.; Russell, D. H.; zhu, J.; Burgess, K. A method for removal of NBOC protecting groups from substrates on TFA-sensitive resins. Tetrahedron Lett., 1998, 39 41, 7439-7442.
175. Lumbierres, M.; Palomo, J. M.; Kragol, G.; Waldmann, H. Solid-phase synthesis of palmitoylated and farnesylated lipopeptides employing the fluoride-labile PTMSEL linker. Tetrahedron Lett., 2006, 47 16, 2671-2674.
176. Yousefi-Salakdeh, E.; Johansson, J.; Stromberg, R. A method for S-and Opalmitoylation of peptides: synthesis of pulmonary surfactant protein-C models. Biochem. J., 1999, 343 Pt 3, 557-562.
177. Bonnet, D.; Bourel, L.; Gras-Masse, H.; Melnyk, O. A novel lipophilic glyoxylic acid derivative for the lipidation of peptides using salt-free hydrazone ligation. Tetrahedron Lett., 2000, 41 51, 10003-10007.
178. Bourel-Bonnet, L.; Bonnet, D.; Malingue, F.; Gras-Masse, H.; Melnyk, O. Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation. Bioconjugate Chem., 2003, 14 2, 494-499.
179. Bourel-Bonnet, L.; Gras-Masse, H.; Melnyk, O. A novel family of amphilic α-oxo aldehydes for the site-specific modification of peptides by two palmitoyl groups in solution or in liposome suspensions. Tetrahedron Lett., 2001, 42 39, 6851-6853.
180. Dubs, P.; Bourel-Bonnet, L.; Subra, G.; Blanpain, A.; Melnyk, O.; Pinel, A. M.; Gras-Masse, H.; Martinez, J. Parallel synthesis of a lipopeptide library by hydrazone-based chemical ligation. J. Comb. Chem., 2007, 9 6, 973-981.